Physician profile
Don D Tran
NPI 1881688950
$2,966.05
in general payments reported to CMS, 2019-2025
23 companies · $675 in 2025
The $675 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $99.94 · 2021: $54.82 · 2022: $427 · 2023: $620 · 2024: $500 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,794.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $415.17 | 2020-2025 | Viberzi, Linzess, Mavyret |
| Amarin Pharma, INC. | $324.72 | 2019 | |
| Novo Nordisk INC | $271.35 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $251.71 | 2022-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $234.93 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Sunovion Pharmaceuticals INC. | $218.93 | 2019-2022 | |
| Gilead Sciences, INC. | $150.00 | 2025 | |
| Lilly USA, LLC | $128.16 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $123.99 | 2022-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $102.62 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.52 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $77.82 | 2023-2024 | Gemtesa |
| Seqirus USA INC | $75.36 | 2023-2025 | Fluad, Flucelvax, Fluad Quadrivalent |
| Nestle Healthcare Nutrition INC. | $74.56 | 2021-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $63.61 | 2025 | Zenpep |
| Merck Sharp & Dohme LLC | $61.29 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Madrigal Pharmaceuticals | $34.20 | 2025 | Rezdiffra |
| Mylan Specialty L.P. | $28.93 | 2024 | Yupelri |
| Abbott Laboratories | $28.23 | 2025 | Esprit |
| Viatris Specialty LLC | $27.27 | 2025 | Yupelri |
| Edwards Lifesciences Corporation | $25.68 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Pfizer INC. | $20.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.